{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:39Z","timestamp":1792839699810,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jfma.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T16:40:19Z","timestamp":1652546419000},"page":"2265-2272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world effectiveness and safety of sofosbuvir\/velpatasvir and glecaprevir\/pibrentasvir for genotype 6 chronic hepatitis C"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6344-320X","authenticated-orcid":false,"given":"Jyh-Jou","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Cheng","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Da","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9331-9018","authenticated-orcid":false,"given":"Pin-Nan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2022.04.020_bib2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","article-title":"Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants","volume":"106","author":"Chen","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.04.020_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/00365521.2018.12027892","article-title":"Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan","volume":"38","author":"Lee","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jfma.2022.04.020_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"H. C. V. C. Polaris Observatory","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib6","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2022.04.020_bib7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4254\/wjh.v7.i12.1617","article-title":"Predictive factors associated with hepatitis C antiviral therapy response","volume":"7","author":"Cavalcante","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ajg.2017.123","article-title":"HCV genotype 6 increased the risk for hepatocellular carcinoma among Asian patients with liver cirrhosis","volume":"112","author":"Lee","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2022.04.020_bib9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.trstmh.2005.10.008","article-title":"Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications","volume":"100","author":"Lee","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jfma.2022.04.020_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jfma.2019.07.021","article-title":"High prevalence of genotype 6 hepatitis C virus infection in Southern Taiwan using Abbott genotype assays","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.04.020_bib11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/apt.14204","article-title":"Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients","volume":"46","author":"Curry","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2022.04.020_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D'Ambrosio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib13","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.04.020_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 Weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib17","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2022.04.020_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3350\/cmh.2020.0058","article-title":"Use of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment","volume":"26","author":"Yap","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","article-title":"Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection","volume":"150","author":"Sulkowski","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2022.04.020_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4254\/wjh.v5.i9.496","article-title":"Hepatitis C genotype 6: a concise review and response-guided therapy proposal","volume":"5","author":"Bunchorntavakul","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/ijc.28753","article-title":"Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma","volume":"135","author":"Lee","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jfma.2022.04.020_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jmv.2001","article-title":"Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan","volume":"65","author":"Yu","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2022.04.020_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2022.04.020_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.04.020_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","article-title":"Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals","volume":"72","author":"Liu","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cgh.2021.07.037","article-title":"Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV Registry Program (TACR)","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2022.04.020_bib29","article-title":"Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment","author":"Liu","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2022.04.020_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cld.33","article-title":"Management of adverse events during the treatment of chronic hepatitis C infection","volume":"1","author":"Nguyen","year":"2012","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jfma.2022.04.020_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1572-0241.2000.01774.x","article-title":"Cholestatic liver diseases and health-related quality of life","volume":"95","author":"Younossi","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2022.04.020_bib32","first-page":"9","article-title":"[Pruritus and the hepatitis C virus. The MULTIVIRC unit]","volume":"125","author":"Dega","year":"1998","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jfma.2022.04.020_bib33","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3748\/wjg.v23.i19.3418","article-title":"Recent advances in the management of pruritus in chronic liver diseases","volume":"23","author":"Tajiri","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2022.04.020_bib34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jfma.2019.06.014","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C","volume":"118","author":"Hsu","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.04.020_bib35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14295","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: real-world effectiveness and safety in Taiwan","volume":"40","author":"Liu","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2022.04.020_bib36","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.jfma.2020.08.010","article-title":"High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir\/pibrentasvir therapy","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.04.020_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection","volume":"67","author":"Toyoda","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2022.04.020_bib38","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622001851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622001851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:48:58Z","timestamp":1760539738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622001851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0929664622001851"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.04.020","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of sofosbuvir\/velpatasvir and glecaprevir\/pibrentasvir for genotype 6 chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}